About EBVAC

Enterprise History

2005
Zhejiang Yibang Biotech Co., Ltd. was officially founded;
April
2006
June
The company’s “Animal New Bio-engineered Vaccine Industrialization Project” was titled as the First Batch of High-tech Industrial Development Project of the year in Hangzhou;
2007
The company was appointed as the Highly Pathogenic Blue-ear Disease Vaccine Manufacturer by the Ministry of Agriculture of PRC;
May
December
The company was awarded the Major Science and Technology Subject of Science Technology Department of Zhejiang Province “Research on the Key Technology of the Industrialization of High Efficient and Stable Highly Pathogenic Blue-ear Disease Vaccine ”;
The company was awarded Hangzhou Major Scientific and Technological Innovation Subject “Adenovirus Vector Avian Influenza H5N1 HA Gene Recombinant Vaccine”;
December
2008
September
The company was appointed as State-supported High-tech Enterprise;
The company was titled as Hangzhou Key Cultivation Growth-type Enterprise
October
October
Research on avian influenza adenovirus recombinant gene vaccine achieved significant breakthroughs and declared the National Invention Patent;
The company was recognized as the public service platform of Hangzhou bio-industry national high-tech industrial base and the technical service sub-platform of biological vaccine and animal testing;
November
November
The company was titled as the Pilot and Industrialization Base of Animal Disease Etiology and Immune Control Key Laboratory of the Ministry of Agriculture;
The company’s R&D Center was identified as Hangzhou High-tech R&D Center;
December
2009
August
The company’s R&D Center passed the narrow inspection of the Science and Technology Department of Zhejiang Province and obtained the identification of Zhejiang High-tech Enterprise Research and Development Center;
The company passed the certification of National Quality Management Security System, Environmental and Safety Management System, Occupational Health and Safety System;
August
November
The company cooperated with the University of Cambridge to establish the Sino-British CAMBIVAC Biological Vaccine R&D Center in the UK which was committed to the research and development of new vaccines;
The company’s “High-tech Industrialization Project of Blue-ear Disease Vaccine and Other Series of Animal Vaccines with an Annual Output of 3 Billion” was approved to become the Special Project of Green Agricultural Biological Products High-tech Industrialization;
December
2010
January
Awarded the “Advanced Investment Unit in Hangzhou”
Awarded the “Great Tax-payer among Investment Enterprises in Hangzhou”;
February
December
The company was awarded the “National Torch Plan Key High-tech Enterprise” certificate;
2011
The company’s PRRSV Vaccine Project won the second prize of Zhejiang Scientific and Technological Achievement Transformation;
June
August
The company officially changed its name into “Zhejiang EBVAC Biotech Co., Ltd.”;
Zhejiang EBVAC Biotech Co., Ltd. successfully passed the re-inspection of GMP;
October
October
The company’s “Development and Industrialization of Porcine Circovirus Vaccine Cloning Type II” was approved to be the 2011 Hangzhou Major Scientific and Technological Innovation Project;
2012
The company’s “Technological Development of Avian Infectious Bronchitis 4/91 Strain Vaccine and Other Six Vaccine Products” and “High-tech Industrialization Project of PRRSV Vaccine and other Series of Animal Vaccines with an Annual Output of 3 Billion” were approved to obtain funding of the 2012 Hangzhou 115 Foreign Knowledge Introduction Project;
May
October
“Key Technology Research Project of Recombinant Porcine Interferon-α Industrialization” was approved to be the 2012 Zhejiang Major Science and Technology Specialized Key Agricultural Project;
2013
The company’s “Duck Infectious Serositis Bivalent Inactivated Vaccine” project was approved to be 2012 Production-Study-Research Cooperation Project in the Economic and Technological Development Zone of Hangzhou;
January
February
The company was recognized as the Patent Pilot Enterprise in the Economic and Technological Development Zone of Hangzhou;
The company achieved the new veterinary drug registration certificates of circovirus bivalent inactivated vaccine (ZJ / C strain) and riemerella anatipestifer (type 1 and 2) bivalent inactivated vaccine;
January
February
The company achieved the new veterinary drug certificate of duck hepatitis live vaccine;